Literature DB >> 14603076

An overview of proton pump inhibitors.

Gabriella Der1.   

Abstract

SUMMARY: Proton pump inhibitors are the standard of treatment for acid-related disorders. These disorders include gastroesophageal reflux disease and its complications (i.e., erosive esophagitis and Barrett's esophagus), peptic ulcer disease, Zollinger-Ellison syndrome, and idiopathic hypersecretion. Proton pump inhibitors are also successfully used for the treatment of Helicobacter pylori infection and upper gastrointestinal bleeding. There are currently five proton pump inhibitors approved by the Food and Drug Administration and available in the United States. These are omeprazole (Prilosec), lansoprazole (Prevacid), rabeprazole (Aciphex), pantoprazole (Protonix), and esomeprazole (Nexium). This review discusses the history of proton pump inhibitors and compares and evaluates the pharmacology including mechanism of action, pharmacokinetics, pharmacodynamics, administration, dosage, and drug interactions. Information regarding therapeutic indications, clinical efficacy, short- and long-term side effects, and cost is also presented. A case presentation offers an analysis of the use of proton pump inhibitors in individualized patient care.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14603076     DOI: 10.1097/00001610-200309000-00003

Source DB:  PubMed          Journal:  Gastroenterol Nurs        ISSN: 1042-895X            Impact factor:   0.978


  13 in total

1.  What is this image? 2019: Image 2 result : Reduction in interfering gastric wall uptake on myocardial perfusion SPECT following a 2-week period of omeprazole withdrawal.

Authors:  Mohsen Qutbi
Journal:  J Nucl Cardiol       Date:  2019-07-29       Impact factor: 5.952

2.  Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people.

Authors:  C Franchi; P M Mannucci; A Nobili; I Ardoino
Journal:  Eur J Clin Pharmacol       Date:  2019-12-18       Impact factor: 2.953

3.  Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.

Authors:  Yohannes T Ghebremariam; Paea LePendu; Jerry C Lee; Daniel A Erlanson; Anna Slaviero; Nigam H Shah; James Leiper; John P Cooke
Journal:  Circulation       Date:  2013-07-03       Impact factor: 29.690

4.  Omeprazole suppresses aggressive cancer growth and metastasis in mice through promoting Snail degradation.

Authors:  Yang Li; Bo-Xue Ren; Hong-Mei Li; Tao Lu; Rong Fu; Zhao-Qiu Wu
Journal:  Acta Pharmacol Sin       Date:  2021-11-16       Impact factor: 7.169

Review 5.  Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.

Authors:  Maria Jose Solana; Jesús López-Herce
Journal:  Eur J Clin Pharmacol       Date:  2009-12-30       Impact factor: 2.953

Review 6.  How May Proton Pump Inhibitors Impair Cardiovascular Health?

Authors:  Roman A Sukhovershin; John P Cooke
Journal:  Am J Cardiovasc Drugs       Date:  2016-06       Impact factor: 3.571

7.  Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.

Authors:  Xu-Wen Guan; Fang Zhao; Jing-Ya Wang; Hai-Yan Wang; Shao-Hua Ge; Xia Wang; Le Zhang; Rui Liu; Yi Ba; Hong-Li Li; Ting Deng; Li-Kun Zhou; Ming Bai; Tao Ning; Hai-Yang Zhang; Ding-Zhi Huang
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

8.  Gastroesophageal reflux in critically ill children: a review.

Authors:  Maria José Solana García; Jesús López-Herce Cid; César Sánchez Sánchez
Journal:  ISRN Gastroenterol       Date:  2013-01-31

9.  Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.

Authors:  Valerie E Fako; Xi Wu; Beth Pflug; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  J Med Chem       Date:  2014-12-29       Impact factor: 7.446

10.  Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer.

Authors:  Bi-Yun Wang; Jian Zhang; Jia-Lei Wang; Si Sun; Zhong-Hua Wang; Lei-Ping Wang; Qun-Ling Zhang; Fang-Fang Lv; En-Ying Cao; Zhi-Min Shao; Stefano Fais; Xi-Chun Hu
Journal:  J Exp Clin Cancer Res       Date:  2015-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.